OLEMA PHARMACEUTICALS, INC. Proceeds from Convertible Debt
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Proceeds from Convertible Debt of $3.00 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2022-02-28
- OLEMA PHARMACEUTICALS, INC. proceeds from convertible debt for the quarter ending 2020-12-31 was $0.00.
- OLEMA PHARMACEUTICALS, INC. proceeds from convertible debt for the quarter ending 2020-09-30 was $0.00.
- OLEMA PHARMACEUTICALS, INC. proceeds from convertible debt for the quarter ending 2020-06-30 was $0.00.
- OLEMA PHARMACEUTICALS, INC. proceeds from convertible debt for the quarter ending 2020-03-31 was $3.00M.
- OLEMA PHARMACEUTICALS, INC. proceeds from convertible debt for fiscal 2020 was $3.00M.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 derived: sum of 3 quarters · filed 2022-02-28 | $3.00M 10-K · filed 2022-02-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $3.00M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $3.00M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $3.00M 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |